A Six-Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Indian Postmenopausal Women With Osteoporosis.
Latest Information Update: 23 Oct 2023
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 21 Nov 2012 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
- 15 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jan 2012 Actual initiation date (Jan 2012) added as reported by ClinicalTrials.gov.